Allarity Therapeutics, Inc. - Common stock (ALLR)
ALLR moved a median of -1.02% 30 minutes after news, and -0.98% by the close. How ALLR actually reacts to news — the realized, point-in-time move the market made, measured across 615 labeled events over the last three years with zero look-ahead.
ALLR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.10% | 39% | 602 |
| 30-min | -1.02% | 33% | 615 |
| 60-min | -1.17% | 33% | 615 |
| to close | -0.98% | 41% | 615 |
| Middle 50% of ALLR reactions | -2.91% to +0.82% |
|---|---|
| Median reaction (30-min) | -1.02% |
| Measured reactions | 615 |
Half of all Allarity Therapeutics, Inc. - Common stock news events land between -2.91% and +0.82% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ALLR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALLR's baseline. Nothing else.
Recent ALLR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Allarity Therapeutics, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +0.77% | -1.89% | |
| Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development | Press release | GlobeNewswire | +2.29% | +8.49% | |
| Form 8-K Allarity Therapeutics, For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -0.52% | |
| Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research | Press release | GlobeNewswire | -2.91% | -5.98% | |
| Form 8-K Allarity Therapeutics, For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | +2.21% | |
| Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development | Press release | GlobeNewswire | -2.15% | -4.31% | |
| Form 8-K Allarity Therapeutics, For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | — | -3.31% | |
| Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement | Press release | GlobeNewswire | -4.54% | -7.58% | |
| Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign | Press release | GlobeNewswire | +0.00% | -2.84% | |
| Form 10-Q Allarity Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.84% | |
| Form 8-K Allarity Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -3.60% | |
| Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration | Press release | GlobeNewswire | -1.68% | -5.04% | |
| Form 8-K Allarity Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | +3.91% | |
| Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic | Press release | GlobeNewswire | +1.56% | +0.78% | |
| Form 8-K Allarity Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | -4.89% | |
| Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 | Press release | GlobeNewswire | -1.48% | +5.93% | |
| Form 8-K Allarity Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.66% | |
| Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers | Press release | GlobeNewswire | +1.45% | +3.62% | |
| Form 10-Q Allarity Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.45% | +3.62% | |
| Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm | Press release | GlobeNewswire | -0.67% | +3.33% | |
| Form 8-K Allarity Therapeutics, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -1.27% | +6.33% | |
| Form 8-K Allarity Therapeutics, For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.71% | |
| Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign | Press release | GlobeNewswire | +3.91% | +9.38% | |
| Form ARS Allarity Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.73% | -4.41% | |
| Form DEF 14A Allarity Therapeutics, For: Jun 26 | SEC filing · Form DEF | SEC EDGAR | -0.73% | -4.41% | |
| Form DEFA14A Allarity Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.73% | -4.41% | |
| Form 8-K Allarity Therapeutics, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -2.17% | -0.72% | |
| Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office | Press release | GlobeNewswire | -0.73% | +0.00% | |
| Form EFFECT Allarity Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.73% | +0.00% | |
| Form S-3/A Allarity Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.45% | -1.03% | |
| Form 8-K Allarity Therapeutics, For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | -2.10% | |
| Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer | Press release | GlobeNewswire | +1.56% | +7.81% | |
| Form PRE 14A Allarity Therapeutics, For: Apr 10 | SEC filing · Form PRE | SEC EDGAR | +1.20% | -6.30% | |
| Form 8-K Allarity Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | +1.80% | |
| Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress | Press release | GlobeNewswire | -0.01% | +6.86% | |
| Form 10-K Allarity Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.01% | +6.86% | |
| Form 8-K Allarity Therapeutics, For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +3.31% | +2.48% | |
| Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization | Press release | GlobeNewswire | -0.01% | +18.09% | |
| Form 8-K Allarity Therapeutics, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +18.09% | |
| Form 8-K Allarity Therapeutics, For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +2.72% | +16.59% | |
| Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need | Press release | GlobeNewswire | +0.20% | +6.33% | |
| Form S-3 Allarity Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.65% | +0.13% | |
| Form 8-K Allarity Therapeutics, For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | -4.26% | |
| Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment | Press release | GlobeNewswire | -2.08% | -7.67% | |
| Form 8-K Allarity Therapeutics, For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | +1.89% | -1.42% | |
| Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders | Press release | GlobeNewswire | -0.98% | +5.88% | |
| Form 8-K Allarity Therapeutics, For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +3.06% | +7.14% | |
| Form 8-K Allarity Therapeutics, For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | +1.75% | |
| Form EFFECT Allarity Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.73% | +1.75% | |
| Form S-3 Allarity Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -2.52% | -9.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALLR section they belong to.
Where else ALLR is measured.
ALLR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Allarity Therapeutics, Inc. - Common stock's median reaction calculated?
Every labeled ALLR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 615 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 33% of ALLR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALLR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.